A first-in-class JAK/ROCK inhibitor, rovadicitinib, for glucocorticoid-refractory or -dependent chronic GVHD

Journal:

Blood

Published:

2025-06-12

DOI:

10.1182/blood.2024026581

Affiliations:

11

Authors:

22

Go to article

Institutions	Authors	Share
The First Affiliated Hospital, Zhejiang University School of Medicine, China	3.666667	0.17
Zhejiang University (ZJU), China	3.666667	0.17
Zhejiang University Medical Center, China	3.666667	0.17
Chia Tai Tianqing Pharmaceutical Group Co. Ltd., China	3.000000	0.14
Second Affiliated Hospital, SCUT, China	2.000000	0.09
Institute of Hematology and Blood Diseases Hospital, CAMS & PUMC, China	2.000000	0.09
The First Affiliated Hospital, USTC, China	1.000000	0.05
The Second Hospital of Hebei Medical University, China	1.000000	0.05
Tongji Hospital (TJH), HUST, China	1.000000	0.05
Nanfang Hospital, China	1.000000	0.05

Interested in Immunology?